secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001104659-24-071512
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised
--------------------------------------------------------------------------------

- Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.
- Non-employee director annual award limit raised to $750K ($1.2M for new directors) effective after stockholder approval.
- All eight director nominees elected, including CEO Anthony Marucci and Chair Karen Shoos, with over 54.6M votes for each.
- Advisory say-on-pay vote approved with 54.2M for, 0.9M against; auditor ratification passed with 57.8M for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465924071512/0001104659-24-071512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465924071512/tm2417134d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer